TwinBeech Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

TwinBeech Capital’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-71,194	Closed	-$934K	–	617
2024 Q3	$934K	Buy	+71,194	New	+$1.08M	0.02%	514

Other funds holding AVDL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

TwinBeech Capital's AVDL Position: Q4 2024 in Review

TwinBeech Capital sold out of Avadel Pharmaceuticals (AVDL) in Q4 2024, closing a stake of 71,194 shares — an estimated $934K sold.

TwinBeech Capital first reported a position in AVDL in Q3 2024 and held it in 1 quarter. The position peaked at $934K in Q3 2024. 159 funds tracked by Wall St. Rank hold AVDL as of Q4 2024.

TwinBeech Capital reported no remaining Avadel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
TwinBeech Capital sold 71,194 Avadel Pharmaceuticals shares in Q4 2024, an estimated $934K.
TwinBeech Capital first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 1 quarter.
TwinBeech Capital's Avadel Pharmaceuticals position peaked at $934K in Q3 2024.
159 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2024.

Based on TwinBeech Capital's 13F filing for Q4 2024, filed 14 Feb 2025.